Viemed Healthcare Inc

VMD remains in a Stage 2 advance with a bullish medium-term bias anchored by a rising 50 and 200 SMA. Short-term price has pulled back into rising EMAs and is oversold, lacking clear acceptance above the 9 and 21 EMA. We recommend stalking for a deeper test of the EMAs or the mid-May swing low support before engaging.

• ↑Q1 revenue of $75.4M grew 28% YoY, driven by sleep therapy demand.
• ↑Free cash flow improved to $2.6M vs –$5.7M a year ago.
• ↓Negative earnings yield indicates stock may be overvalued relative to peers.